Mei Ri Jing Ji Xin Wen·2025-10-31 01:05Group 1 - The core viewpoint of the articles highlights the strong performance of Kanglong Chemical in Q3, with a revenue of 3.645 billion yuan, representing a year-on-year growth of 13.44%, and a net profit of 440 million yuan, which is a significant increase of 42.52% compared to last year [1] - Kanglong Chemical has raised its full-year revenue growth target to 12-16% based on the performance in the first three quarters of the year [1] - The company announced the acquisition of 82.54% of Baiaode for 1.346 billion yuan, enhancing its capabilities in drug discovery through comprehensive services from gene analysis to cryo-electron microscopy [1] Group 2 - The recent strong performance reports from leading CXO companies like WuXi AppTec and Kanglong Chemical have boosted market confidence in the innovative drug sector [1] - The innovative drug sector is expected to see more policy-driven catalysts as concerns over market bubbles have diminished following a phase of adjustment [1] - Related ETFs in the innovative drug industry include the Hong Kong Stock Connect Medical ETF (520510), which has a leading CXO content, and the Hang Seng Pharmaceutical ETF (159892), which emphasizes innovation [2]